(HealthDay News) — The U.S. Food and Drug Administration has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active immunization against invasive meningococcal disease (IMD), ...

The story has been updated to correct the FDA approval date to Friday, February 14 On Friday, February 14, the FDA approved ...

The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...

Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...

GSK’s MenABCWY vaccine is an injectable suspension intended for intramuscular use. It comes with a vial of lyophilised ...

Meningococcal Vaccine MarketThe global meningococcal vaccine market is experiencing significant growth, driven by rising ...

Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...

Meningococcal infections can lead to severe, sometimes deadly, bloodstream infections, and severe swelling in the brain and ...

Penmenvy combines the antigenic components of Bexsero (meningococcal Group B vaccine) and Menveo (meningococcal Groups A, C, Y, and W-135 oligosaccharide diphtheria CRM197 conjugate vaccine).

He added that IMD leads to death in a matter of hours due to its rapid course of progression, including an average incubation ...

The FDA approved GSK’s pentavalent meningococcal vaccine to protect children and young adults aged 10 to 25 years against ...

Background: Given the broad age range across which the quadrivalent meningococcal conjugate vaccine MenACWY-CRM is used, coadministration with routine vaccines should be evaluated across age ...